Cereno Scientific AB (FRA:4A1) Payments of Debt: €-17.45 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4A1 Cereno Scientific AB FRA:4A1
39 GF Score
Price €0.42
! 3 Warning Signs
View Full Analysis

What is Cereno Scientific AB Payments of Debt?

Cereno Scientific AB FRA:4A1 +0.62% 39 Payments of Debt is €-17.45 Mil as of Mar. 2026. GuruFocus rates FRA:4A1 with a GF Score™ of 39/100. The stock has 3 warning signs investors should review.

Cereno Scientific AB's Payments of Debt for the three months ended in Mar. 2026 was €0.00 Mil.

Cereno Scientific AB's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was €-17.45 Mil.

Cereno Scientific AB Payments of Debt Related Terms

Cereno Scientific AB Payments of Debt Historical Data

* Premium members only.

The historical data trend for Cereno Scientific AB's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cereno Scientific AB Payments of Debt Chart

Cereno Scientific AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.97 -0.46 0.00 0.00 -18.38

Cereno Scientific AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.91 -0.91 0.00 -16.54 0.00
FRA:4A1
39GF Score
Cereno Scientific AB FRA:4A1
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cereno Scientific AB Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-17.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of €-17.45 Mil mean?
Cereno Scientific AB (FRA:4A1) has a Payments of Debt of €-17.45 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Cereno Scientific AB and its competitors.
Is Cereno Scientific AB's Payments of Debt too high?
Cereno Scientific AB's current Payments of Debt is €-17.45 Mil. Overall, Cereno Scientific AB has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Cereno Scientific AB's Payments of Debt compare to ZTS?
Cereno Scientific AB's Payments of Debt of €-17.45 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Drug Manufacturers company?
A good Payments of Debt depends on the Drug Manufacturers industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Cereno Scientific AB and its competitors. Cereno Scientific AB's current Payments of Debt is €-17.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cereno Scientific AB stock overvalued right now?
Cereno Scientific AB (FRA:4A1) has a current Payments of Debt of €-17.45 Mil. The current Payments of Debt is €-17.45 Mil. Cereno Scientific AB's overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Cereno Scientific AB (FRA:4A1), the current Payments of Debt is €-17.45 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cereno Scientific AB Business Description

Other Exchanges CRNO B:Sweden
Address Forandringens gata 10, Molndal, SWE, 431 53
Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's program, CS1, is a phase two dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. It also evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.
39GF Score

Get the complete analysis for FRA:4A1

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.42
Price